High bleeding risk patients with acute coronary syndromes treated with contemporary drug-eluting stents and Clopidogrel or Ticagrelor: Insights from CHANGE DAPT
The prospective observational CHANGE DAPT study compared clopidogrel versus ticagrelor-based dual antiplatelet (DAPT) regimens in consecutive patients with acute coronary syndrome (ACS), treated with percutaneous coronary intervention (PCI) with contemporary drug-eluting stents (DES). During the ticagrelor period (TP, May 2014 –August 2015) there were more major bleedings than during the clopidogrel period (CP, December 2012–April 2014).
Source: International Journal of Cardiology - Category: Cardiology Authors: Paolo Zocca, Marlies M. Kok, Liefke C. van der Heijden, K. Gert van Houwelingen, Marc Hartmann, Frits H.A.F. de Man, Martin G. Stoel, J.(Hans) W. Louwerenburg, Iris L. Knottnerus, Gerard C.M. Linssen, Carine J.M. Doggen, Clemens von Birgelen Source Type: research
More News: Angioplasty | Bleeding | Cardiology | Clopidogrel | Coronary Angioplasty | Heart | Percutaneous Coronary Intervention | Plavix | Study